Related Experiment Video
Updated: Jan 9, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
Published on: October 3, 2019
Calpain activation disrupts ER-Phagy and leads to mitochondrial damage in hearts treated with isoproterenol
Qun Chen1, Ling Li2, Jeremy Thompson1
1Department of Medicine (Division of Cardiology, Pauley Heart Center), Virginia Commonwealth University, Richmond, VA, 23298, United States of America.
Abstract:
The endoplasmic reticulum (ER) is a dynamic organelle whose homeostasis is maintained by ER-phagy (ERPG). Under conditions of ER stress, calcium-dependent cysteine proteases-specifically calpain 1 and calpain 2 (CPN1/2)-are activated and contribute to mitochondrial damage. Isoproterenol (ISO) administration is a widely used experimental model for inducing cardiac dysfunction. In this study, we hypothesize that impaired ERPG worsens ER stress in ISO-treated hearts, leading to mitochondrial dysfunction through the activation of CPN1/2. Male C57BL/6 mice (2-3 months old) received ISO at a dose of 100 mg/kg via daily intraperitoneal (IP) injection for five consecutive days. Cardiac function, ER stress, and mitochondrial function were assessed before ISO treatment, and at 1-, 2-, and 4- weeks following exposure. Cardiac dysfunction was evident two weeks after ISO administration. ER stress began to increase one week after ISO treatment and continued to intensify at 2 and 4 weeks. Activation of cytosolic CPN1/2 was observed at 1 week. The content of FAM134B-a key regulator of ERPG-was reduced by 2 weeks post-treatment. Incubation experiments showed that purified CPN1 cleaves FAM134B, supporting its role as a direct target. Mitochondrial respiration, including cytochrome oxidase activity, declined two weeks after ISO exposure. This decline was associated with a loss of cytochrome c and reduced levels of ferrochelatase, both contributing to impaired mitochondrial oxidative capacity. These findings suggest that reducing ER stress may be an effective therapeutic strategy to mitigate contractile dysfunction with cardiac disease.
More Related Videos
09:26Optical Mapping of Intra-Sarcoplasmic Reticulum Ca2+ and Transmembrane Potential in the Langendorff-perfused Rabbit Heart
Published on: September 10, 2015
09:36Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Myocarditis I: Introduction
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy II: Dilated Cardiomyopathy